Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).

Article  CAS  PubMed  Google Scholar 

Dougan, M., Luoma, A. M., Dougan, S. K. & Wucherpfennig, K. W. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184, 1575–1588 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).

Article  PubMed  Google Scholar 

Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).

Article  CAS  PubMed  Google Scholar 

Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576 (2022).

Article  CAS  PubMed  Google Scholar 

Maruhashi, T., Sugiura, D., Okazaki, I. & Okazaki, T. LAG-3: from molecular functions to clinical applications. J. Immunother. Cancer 8, e001014 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).

Article  CAS  PubMed  Google Scholar 

Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).

Article  PubMed  Google Scholar 

Molina, G. E. et al. Temporal trends and outcomes among patients admitted for immune‐related adverse events: a single‐center retrospective cohort study from 2011 to 2018. Oncologist 26, 514–522 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnaud‐Coffin, P. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int. J. Cancer 145, 639–648 (2019).

Article  PubMed  Google Scholar 

Abu-Shawer, O. et al. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J. Immunother. Cancer 8, e000992 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Plaçais, L. et al. Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun. 3, fcab220 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Dubey, D. et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann. Neurol. 87, 659–669 (2020).

Article  PubMed  Google Scholar 

Rossi, S. et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J. Neurol. 270, 2975–2986 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1–8 (2016).

Article  Google Scholar 

Hyun, J.-W., Kim, K. H., Kim, S.-H. & Kim, H. J. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at National Cancer Center in Korea. J. Cancer Res. Clin. Oncol. 149, 5583–5589 (2023).

Article  PubMed  Google Scholar 

Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Farina, A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 5, fcad169 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Kao, J. C. et al. Neurological complications associated with anti–programmed death 1 (PD-1) antibodies. JAMA Neurol. 74, 1216–1222 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Farina, A., Villagrán-García, M., Vogrig, A. & Joubert, B. Central nervous system adverse events of immune checkpoint inhibitors. Curr. Opin. Neurol. 37, 345–352 (2024).

Article  CAS  PubMed  Google Scholar 

Guidon, A. C. et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J. Immunother. Cancer 9, e002890 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Dubey, D. et al. Varied phenotypes and management of immune checkpoint inhibitor—a neuropathies. Neurology 93, e1093–e1103 (2019).

Article  CAS  PubMed  Google Scholar 

Marini, A. et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96, 754–766 (2021).

Article  CAS  PubMed  Google Scholar 

Sechi, E. et al. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95, e2442–e2452 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggiero, R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Front. Immunol. 14, 1134436 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amato, A. A. & Ropper, A. H. Sensory ganglionopathy. N. Engl. J. Med. 383, 1657–1662 (2020).

Article  PubMed  Google Scholar 

Chompoopong, P. et al. Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J. Neurol. Neurosurg. Psychiatry 93, 112 (2022).

Article  PubMed  Google Scholar 

Löffel, N. B., Rossi, L. N., Mumenthaler, M., Lütschg, J. & Ludin, H.-P. The Landry–Guillain–Barré syndrome: complications, prognosis and natural history in 123 cases. J. Neurol. Sci. 33, 71–79 (1977).

Article